Aurobindo Pharma Limited has submitted Copy of Newspaper Publication with regard to post buyback public advertisement.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has completed its share buyback program via the tender offer route under SEBI regulations. The company bought back 50,12,726 equity shares (out of a maximum of 54,23,728 offered) at ₹1,475 per share, utilizing ₹799.99 crore (99.99% of the ₹800 crore budget). The buyback size represented 3.93% of total paid-up equity capital. A total of 2,904.13 lakh shares were tendered — approximately 5.43 times the maximum buyback volume — indicating strong investor participation. The Registrar (KFin Technologies) completed verification and the Clearing Corporation accepted all valid bids on May 7, 2026. Share extinguishment is currently underway and will be completed by May 16, 2026.
The buyback was fully subscribed at nearly 5.5x, signaling strong shareholder confidence. Nearly all allocated funds (₹799.99 crore of ₹800 crore) were deployed, which will reduce equity capital and is typically EPS-accretive. No immediate impact on the stock is expected as the outcome was broadly in line with expectations.